T2 Biosystems (TTOO)
OTHER OTC:TTOO
Top Page
No summary available
Positive Factors
Revenue Growth
The 34% revenue growth indicates strong demand for T2 Biosystems' products, suggesting effective market penetration and potential for sustained growth.
Negative Factors
Financial Instability
Negative equity and high leverage highlight financial instability, posing risks to operational sustainability and limiting strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The 34% revenue growth indicates strong demand for T2 Biosystems' products, suggesting effective market penetration and potential for sustained growth.
Read all positive factors
T2 Biosystems (TTOO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.61K
Dividend YieldN/A
Average Volume (3M)18.99K
Price to Earnings (P/E)―
Beta (1Y)-9.21
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees113
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding28,045,418
10 Day Avg. Volume30,842
30 Day Avg. Volume18,993
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.58
Price to Sales (P/S)2.28
P/FCF Ratio-0.34
Enterprise Value/Market Cap6.03K
Enterprise Value/Revenue4.40
Enterprise Value/Gross Profit-5.67
Enterprise Value/Ebitda-0.86
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
T2 Biosystems Business Overview & Revenue Model
Company Description
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpur...
How the Company Makes Money
T2 Biosystems generates revenue primarily through the sale of its diagnostic instruments and related consumable products. The company's core revenue stream comes from the sale and leasing of the T2Dx Instrument, along with the sales of test panels...
T2 Biosystems Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.68M | 7.19M | 22.30M | 28.06M | 18.13M | 8.34M |
| Gross Profit | -5.97M | -8.17M | 1.17M | 7.36M | -3.15M | -8.43M |
| EBITDA | -39.51M | -43.88M | -54.87M | -41.13M | -36.71M | -48.30M |
| Net Income | -42.95M | -50.08M | -62.00M | -49.24M | -46.80M | -59.01M |
Balance Sheet | ||||||
| Total Assets | 18.08M | 34.80M | 34.39M | 60.54M | 79.08M | 28.49M |
| Cash, Cash Equivalents and Short-Term Investments | 2.08M | 15.69M | 10.33M | 32.24M | 42.19M | 11.03M |
| Total Debt | 18.94M | 49.50M | 59.22M | 58.32M | 56.92M | 44.77M |
| Total Liabilities | 29.79M | 62.83M | 74.36M | 73.44M | 70.35M | 62.49M |
| Stockholders Equity | -11.71M | -28.04M | -39.97M | -12.90M | 8.73M | -34.01M |
Cash Flow | ||||||
| Free Cash Flow | -36.62M | -48.33M | -50.97M | -39.33M | -44.02M | -46.12M |
| Operating Cash Flow | -36.59M | -48.14M | -50.63M | -38.87M | -43.22M | -45.36M |
| Investing Cash Flow | -26.00K | -192.00K | 9.66M | 24.79M | -36.26M | -761.00K |
| Financing Cash Flow | 14.38M | 52.69M | 29.05M | 20.54M | 85.61M | 6.35M |
T2 Biosystems Technical Analysis
Negative
0.01
Price Trends
0.01
Negative
0.02
Negative
Market Momentum
>-0.01
Positive
47.27
Neutral
51.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TTOO, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.27 is Neutral, neither overbought nor oversold. The STOCH value of 51.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TTOO.
T2 Biosystems Risk Analysis
T2 Biosystems disclosed 64 risk factors in its most recent earnings report. T2 Biosystems reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
T2 Biosystems Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $5.61K | ― | ― | ― | ― | ― | |
57 Neutral | $50.03M | -101.61 | -2.78% | ― | 30.95% | 59.67% | |
56 Neutral | $131.71M | -1.46 | -302.55% | ― | 22.29% | 31.93% | |
51 Neutral | $6.44M | -0.28 | -537.60% | ― | ― | 98.86% | |
47 Neutral | $25.48M | -1.17 | 76.82% | ― | 14.48% | 36.83% | |
44 Neutral | $4.92M | -0.85 | -197.93% | ― | 3.26% | 65.96% |
* Healthcare Sector Average
TTOO
T2 Biosystems
0.01
-0.10
-90.91%
VNRX
VolitionRX
0.16
-0.33
-67.15%
PRPO
Precipio
28.50
22.90
408.93%
NDRA
ENDRA Life Sciences
4.96
1.80
56.96%
BDSX
Biodesix
12.14
0.70
6.12%
INBS
Intelligent Bio Solutions
2.77
-9.83
-78.02%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―